$5.51
3.76% today
Nasdaq, Apr 03, 06:48 pm CET
ISIN
US19240Q2012
Symbol
COGT
Sector
Industry

Cogent Biosciences Inc Stock price

$5.72
-1.28 18.29% 1M
-5.00 46.64% 6M
-2.08 26.67% YTD
-1.03 15.26% 1Y
-2.57 31.00% 3Y
+4.32 308.57% 5Y
-38.72 87.13% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.07 1.21%
ISIN
US19240Q2012
Symbol
COGT
Sector
Industry

Key metrics

Market capitalization $651.22m
Enterprise Value $492.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.34
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-275.94m
Free Cash Flow (TTM) Free Cash Flow $-208.36m
Cash position $287.08m
EPS (TTM) EPS $-2.47
P/E forward negative
Short interest 11.47%
Show more

Is Cogent Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Cogent Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Cogent Biosciences Inc forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Cogent Biosciences Inc forecast:

Buy
75%
Hold
25%

Financial data from Cogent Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 4.40 4.40
23% 23%
-
-4.40 -4.40
23% 23%
-
- Selling and Administrative Expenses 39 39
26% 26%
-
- Research and Development Expense 228 228
34% 34%
-
-272 -272
33% 33%
-
- Depreciation and Amortization 4.40 4.40
23% 23%
-
EBIT (Operating Income) EBIT -276 -276
33% 33%
-
Net Profit -256 -256
33% 33%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cogent Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cogent Biosciences Inc Stock News

Neutral
GlobeNewsWire
9 days ago
Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics
Neutral
GlobeNewsWire
27 days ago
WALTHAM, Mass. and BOULDER, Colo.
Neutral
GlobeNewsWire
about one month ago
65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo.
More Cogent Biosciences Inc News

Company Profile

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Robbins
Employees 205
Founded 2014
Website www.cogentbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today